Pharma Gets The Lowdown On New EMA Processes For Proactive Publication Of Clinical Trial Data
This article was originally published in SRA
The European Medicines Agency has finalized guidance to help implement its policy on the proactive publication of clinical trial data from drug applications submitted for approval from January 20151,2.
You may also be interested in...
The European Medicines Agency is looking for a clear indication from the EU courts on whether its approach to transparency – as defined in its access to documents policy – is correct.
As the European Medicines Agency's policy on access to documents faces yet another legal challenge, the European Confederation of Pharmaceutical Entrepreneurs is hoping the verdict will demystify what constitutes commercially confidential information in a marketing authorization application.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.